Effect of sertraline on intradialytic hypotension: a randomized controlled trial

F. Ghahremanfard, Gholam Ali Mahdavi, M. Mirmohammadkhani, Maliheh Yarmohammadi
{"title":"Effect of sertraline on intradialytic hypotension: a randomized controlled trial","authors":"F. Ghahremanfard, Gholam Ali Mahdavi, M. Mirmohammadkhani, Maliheh Yarmohammadi","doi":"10.34172/npj.2022.10492","DOIUrl":null,"url":null,"abstract":"Introduction: Intradialytic hypotension is an important and common complication of hemodialysis. However, it seems that selective serotonin reuptake inhibitors (SSRIs) can manage patients’ blood pressure during hemodialysis. Objectives: The present study aimed to investigate the effect of sertraline on intradialytic hypotension of the patients under hemodialysis. Patients and Methods: The present randomized controlled trial included 18 patients under hemodialysis for end-stage renal disease (ESRD). The patients were randomly divided into the intervention and control groups. The intervention group received sertraline solely for intradialytic hypotension management, while the control group did not receive such intervention. The blood pressure assessments were conducted before, during, and after hemodialysis in both groups, then the data were analyzed. Results: According to our results, the participants’ mean age was 63.72±9.91 years. The mean systolic and diastolic blood pressures were higher in the intervention group than in the control group before the hemodialysis. However, this difference was not significant for systolic blood pressure (P=0.279), while it was significant for diastolic blood pressure (P=0.02). Additionaly, no significant intergroup difference in systolic and diastolic blood pressure during and after hemodialysis was detected (P>0.05). Conclusion: Sertraline had no significant effect on systolic and diastolic blood pressure during and after hemodialysis. However, it increased the mean systolic and diastolic blood pressure before hemodialysis which could prevent pre-dialytic hypotension without significant side effects. Therefore, it can be effective in preventing hypotension in patients under hemodialysis. Trial Registration: The trial protocol has been approved by the Iranian Registry of Clinical Trial (identifier: IRCT2017080625732N23; https://en.irct.ir/trial/21499, ethical approval code; IR.SEMUMS.REC.1395.156).","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephropharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/npj.2022.10492","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Intradialytic hypotension is an important and common complication of hemodialysis. However, it seems that selective serotonin reuptake inhibitors (SSRIs) can manage patients’ blood pressure during hemodialysis. Objectives: The present study aimed to investigate the effect of sertraline on intradialytic hypotension of the patients under hemodialysis. Patients and Methods: The present randomized controlled trial included 18 patients under hemodialysis for end-stage renal disease (ESRD). The patients were randomly divided into the intervention and control groups. The intervention group received sertraline solely for intradialytic hypotension management, while the control group did not receive such intervention. The blood pressure assessments were conducted before, during, and after hemodialysis in both groups, then the data were analyzed. Results: According to our results, the participants’ mean age was 63.72±9.91 years. The mean systolic and diastolic blood pressures were higher in the intervention group than in the control group before the hemodialysis. However, this difference was not significant for systolic blood pressure (P=0.279), while it was significant for diastolic blood pressure (P=0.02). Additionaly, no significant intergroup difference in systolic and diastolic blood pressure during and after hemodialysis was detected (P>0.05). Conclusion: Sertraline had no significant effect on systolic and diastolic blood pressure during and after hemodialysis. However, it increased the mean systolic and diastolic blood pressure before hemodialysis which could prevent pre-dialytic hypotension without significant side effects. Therefore, it can be effective in preventing hypotension in patients under hemodialysis. Trial Registration: The trial protocol has been approved by the Iranian Registry of Clinical Trial (identifier: IRCT2017080625732N23; https://en.irct.ir/trial/21499, ethical approval code; IR.SEMUMS.REC.1395.156).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
舍曲林对溶性低血压的影响:一项随机对照试验
导读:分析性低血压是血液透析中一种重要而常见的并发症。然而,选择性血清素再摄取抑制剂(SSRIs)似乎可以控制血液透析期间患者的血压。目的:探讨舍曲林对血液透析患者溶栓性低血压的影响。患者和方法:本随机对照试验包括18例终末期肾病(ESRD)血液透析患者。将患者随机分为干预组和对照组。干预组单纯使用舍曲林治疗溶栓性低血压,对照组不使用舍曲林治疗。两组患者分别在血液透析前、透析中、透析后进行血压评估,并进行数据分析。结果:受试者平均年龄为63.72±9.91岁。干预组患者血液透析前的平均收缩压和舒张压均高于对照组。然而,收缩压的差异无统计学意义(P=0.279),而舒张压的差异有统计学意义(P=0.02)。两组患者血液透析前后收缩压、舒张压差异无统计学意义(P < 0.05)。结论:舍曲林对血液透析前后的收缩压和舒张压无明显影响。然而,它提高了血液透析前的平均收缩压和舒张压,可以预防透析前低血压,无明显的副作用。因此,它可以有效地预防血液透析患者的低血压。试验注册:试验方案已获得伊朗临床试验注册中心批准(标识符:IRCT2017080625732N23;https://en.irct.ir/trial/21499,道德审批守则;IR.SEMUMS.REC.1395.156)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Nephropharmacology
Journal of Nephropharmacology Medicine-Pharmacology (medical)
CiteScore
1.70
自引率
0.00%
发文量
18
审稿时长
4 weeks
期刊最新文献
Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial Renal insufficiency in breast cancer patients; a review study The Mayo Clinic consensus report on membranous nephropathy; a promising step toward better treating the disease Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology Oncocardiology: close collaboration between oncologists, cardiologists, and nephrologists
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1